Agents that target epidermal growth factor receptor (EGFR) potentially exert antitumour effects by inhibiting tumour cell proliferation and survival, as well as reducing the secretion of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor that stimulate tumour neoangiogenesis (Perrotte et al, 1999; Woodburn, 1999; Ciardiello et al, 2001). Here, EGFR is linked to neoplasm.